TABLE 1

Selected NLRP3 associated diseases and their activators

DiseaseActivatorsReference
CAPSMutation in the NLRP3 geneHoffman and Brydges (2011)
NASHCholesterol crystalsMridha et al. (2017)
AlzheimerAβ plaquesHalle et al. (2008)
Parkinsonα-SynucleinCodolo et al. (2013)
Cardiovascular diseaseCholesterol crystals, oxidized LDLJanoudi et al. (2016)
OsteoarthritisHydroxyapetiteJin et al. (2011)
GoutMonosodium urateMartinon et al. (2006)
PseudogoutCalcium pyrophosphateMartinon et al. (2006)
NephrocalcinosisCalcium saltsAnders et al. (2018)
Type II diabetesFree fatty acid (FFA), islet amyloid polypeptide (IAPP)Dixit (2013)
Sjogren syndromeInflammagenic DNAVakrakou et al. (2018)
Sickle cell disease (SCD)HemeVogel et al. (2017)
AMDDrusen’s deposits, Alu RNADoyle et al. (2012); Tarallo et al. (2012)
InfectionsVirus, fungus, and bacteriaSkeldon and Saleh (2011)
Cerebral malariaHemozoinDostert et al. (2009)
AsbestosisAsbestosCassel et al. (2008)
Contact hypersensitivityNickelLi and Zhong (2014)
SunburnUV lightHasegawa et al. (2016)
SilicosisSilicaCassel et al. (2008)
Cystic fibrosisCeramideGrassmé et al. (2014)
Inflammatory bowel diseaseDeoxycholic acidZhao et al. (2016)
NephrocalcitosisCalcium saltsMulay et al. (2013)
ALSSOD1G93A and TDP-43 proteinsDeora et al. (2020)
Myelodysplastic syndromeS100A8/A9Sallman and List (2019)
UveitisMembrane attack complex depositionKumar et al. (2018)